BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 18288134)

  • 1. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
    Cambier N; Renneville A; Cazaentre T; Soenen V; Cossement C; Giraudier S; Grardel N; Laï JL; Rose C; Preudhomme C
    Leukemia; 2008 Jul; 22(7):1454-5. PubMed ID: 18288134
    [No Abstract]   [Full Text] [Related]  

  • 2. [Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].
    Takizawa M; Yokohama A; Sekigami T; Koiso H; Ishizaki T; Mitsui T; Ogawa Y; Saitoh T; Handa H; Tsukamoto N; Murakami H; Nojima Y
    Rinsho Ketsueki; 2014 Jun; 55(6):687-91. PubMed ID: 24975338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
    Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
    Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
    [No Abstract]   [Full Text] [Related]  

  • 4. Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.
    Tefferi A; Levitt R; Lasho TL; Knudson RA; Ketterling RP
    Eur J Haematol; 2010 Jul; 85(1):86-7. PubMed ID: 20408872
    [No Abstract]   [Full Text] [Related]  

  • 5. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.
    Bee PC; Gan GG; Nadarajan VS; Latiff NA; Menaka N
    Int J Hematol; 2010 Jan; 91(1):136-9. PubMed ID: 20047097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.
    Inami M; Inokuchi K; Okabe M; Kosaka F; Mitamura Y; Yamaguchi H; Dan K
    Leukemia; 2007 May; 21(5):1103-4. PubMed ID: 17301812
    [No Abstract]   [Full Text] [Related]  

  • 7. Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.
    Zhou A; Knoche EM; Engle EK; Fisher DA; Oh ST
    Blood Cancer J; 2015 Oct; 5(10):e351. PubMed ID: 26430722
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
    Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
    Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
    [No Abstract]   [Full Text] [Related]  

  • 9. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.
    Campiotti L; Appio L; Solbiati F; Ageno W; Venco A
    Leuk Res; 2009 Nov; 33(11):e212-3. PubMed ID: 19589593
    [No Abstract]   [Full Text] [Related]  

  • 10. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
    Pingali SR; Mathiason MA; Lovrich SD; Go RS
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):E25-9. PubMed ID: 19858050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
    Cornea MI; Levrat E; Pugin P; Betticher DC
    J Med Case Rep; 2015 Apr; 9():30. PubMed ID: 26187587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.
    Véronèse L; Tchirkov A; Richard-Pebrel C; Ledoux-Pilon A; Fleury J; Chaleteix C; Goumy C; Gouas L; Berger MG; Vago P; Bay JO; Tournilhac O
    Leuk Res; 2010 Apr; 34(4):e94-6. PubMed ID: 19833389
    [No Abstract]   [Full Text] [Related]  

  • 13. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
    Krämer A; Reiter A; Kruth J; Erben P; Hochhaus A; Müller M; Cross NC; Jones AV; Ho AD; Hensel M
    Lancet Oncol; 2007 Jul; 8(7):658-60. PubMed ID: 17613428
    [No Abstract]   [Full Text] [Related]  

  • 14. The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression - an overlapping myeloproliferative disorder or two distinct diseases? - case report.
    Ursuleac I; Colita A; Adam T; Jardan C; Ilea A; Coriu D
    J Med Life; 2013 Mar; 6(1):34-7. PubMed ID: 23599815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
    Garber K
    J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
    [No Abstract]   [Full Text] [Related]  

  • 16. [Polycythemia vera developed after a major molecular response to imatinib mesylate treatment in a patient with chronic myelogenous leukemia].
    Jomen W; Kuroda H; Matsuno T; Sato M; Yamada M; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Kato J; Nojiri S
    Rinsho Ketsueki; 2014 Mar; 55(3):360-5. PubMed ID: 24681942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia.
    Wang X; Tripodi J; Kremyanskaya M; Blouin A; Roda P; Hoffman R; Najfeld V
    Blood; 2013 Feb; 121(7):1238-9. PubMed ID: 23411734
    [No Abstract]   [Full Text] [Related]  

  • 18. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
    Michiels JJ; Pich A; De Raeve H; Gadisseur A
    Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
    [No Abstract]   [Full Text] [Related]  

  • 19. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
    Gattenlohner S; Völker HU; Etschmann B; Einsele H; Müller-Hermelink HK
    Am J Hematol; 2009 May; 84(5):306-7. PubMed ID: 18951468
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib.
    Cayuela JM; Rousselot P; Nicolini F; Espinouse D; Ollagnier C; Bui-Thi MH; Chabane K; Raffoux E; Callet-Bauchu E; Tigaud I; Magaud JP; Hayette S
    Leukemia; 2005 Dec; 19(12):2334-6. PubMed ID: 16224485
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.